New York (ots/PRNewswire) - - Prototype Research Kits Approach Commercialization Phase and Target the Growing Field of Genomic-Based Molecular Diagnostics Xenomics, Inc. (OTC Bulletin Board: XNOM; FWB:XE7), the source of next-generation medical DNA diagnostic tests, today announced that it has developed a new method for the isolation of low molecular ...
Basel (ots/PRNewswire) - - Results Unveiled at ICAAC Show That Over 90% of Treatment-Experienced Patients Achieve Treatment Goal of Undetectable Viral Load Exciting new clinical data demonstrate that 90 to 95 percent of treatment-experienced HIV patients who initiate therapy with FUZEON(R) (enfuvirtide) ...
Madrid (ots/PRNewswire) - PharmaMar today announced the successful planned review by the Independent Data Monitoring Committee (IDMC) of the YONDELIS(R) (trabectedin) Phase III pivotal clinical trial in ovarian cancer, known as OVA-301. The IDMC recommended that the present study should continue without ...
Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. announced today that the Company received a No Objection Letter from Health Canada to conduct a pivotal Phase III European /Canadian clinical trial for the treatment of moderate to severe psoriasis with its lead immunosuppressive drug, ISA247. The Company ...
Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. announced today that the Company has been issued European Patent No. EP0991660 for its lead immunosuppressive drug, ISA247. The patent entitled "DEUTERATED AND UNDEUTERATED CYCLOSPORINE ANALOGS AND THEIR USE AS IMMUNOMODULATING AGENTS" is the ninth patent to be issued internationally in this patent family. ...
Macclesfield, England (ots/PRNewswire) - - For International Journalists - Not for US Media New data, presented for the first time today, show that a combination of ARIMIDEX(TM)(anastrozole) plus Herceptin (trastuzumab) is a better treatment option than hormonal therapy alone, for women with a certain ...
Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. announced today that the Company received approval from the German Competent Authority to conduct a pivotal Phase III clinical trial for the treatment of moderate to severe psoriasis with its lead immunosuppressive drug, ISA247. The Phase III ...
NEW- YORK, September 29 (ots/PRNewswire) - Sanofi Pasteur, the vaccines business of sanofi-aventis, and the Pediatric Dengue Vaccine Initiative (PDVI) announced today their partnership to help develop and make a Dengue vaccine widely available for the global prevention of Dengue fever, the second most widespread tropical disease after malaria. Dengue fever ...
Istanbul, Turkey (ots/PRNewswire) - PharmaMar, the biopharmaceutical company specialising in cancer therapy, announces today that it is to present new data from two of its clinical compounds, Kahalalide F and Aplidin(R), at the 31st European Society for Medical Oncology Congress (ESMO) being held in Istanbul, Turkey from 29 September to 3 October 2006. Data will ...
Alderley Park, England (ots/PRNewswire) - - First Patient Enrolled in Pivotal International Randomised, Double-Blind Study of Vandetanib Versus Erlotinib FOR NON-US HEALTHCARE PROFESSIONAL PRESS ONLY AstraZeneca (NYSE:AZN) today announced the start of enrolment into a new Phase III study of the novel ...
Cordis Medizinische Apparate GmbH
Paris (ots/PRNewswire) - - Shipment of First Third-Generation Drug-eluting Stent Starts Cordis Corporation, the world leader in the drug-eluting stent market, announced today the launch of the CYPHER SELECT(TM) Plus Stent. The first third-generation drug-eluting stent is now available to physicians and patients in many markets around the world, including countries in Western and Eastern Europe, Asia Pacific ...
SWIFTWATER, Pennsylvania & LYON, France, September 26 (ots/PRNewswire) - - Flu Vaccine Based on New Technology Within U.S. Government Preparedness Program Sanofi pasteur, the vaccines business of the sanofi-aventis Group (NYSE: SNY), initiated its first clinical study today with a new generation of seasonal influenza vaccine produced using cell ...
Lyon, France (ots/PRNewswire) - Sanofi pasteur, the vaccines business of the sanofi-aventis Group, has within the framework of FLUPAN, a collaborative research project funded by the European Commission, generated the first clinical trial lot of a new generation of H7N1 pandemic vaccine. This trial will broaden ...
World Federation for Mental Health
Paris (ots/PRNewswire) - - Multi-National Survey Highlights Gaps in PCPs Knowledge About Depression and Painful Physical Symptoms Nine of 10 young primary care physicians (PCPs) believe medical school training about depression -- specifically regarding its painful physical symptoms -- needs to be improved, according to findings from a multi-national survey ...
New York (ots/PRNewswire) - - Lyrica's neuropathic pain indication broadened to include central nerve pain; Central nerve pain is associated with conditions such as spinal cord injury, stroke, and multiple sclerosis - A robust and unprecedented clinical program involving more than 10,000 patients supports Lyrica's efficacy and safety in ...
Paris (ots/PRNewswire) - - For Healthcare and Medical Reporters (non-US) Bipolar disorder is the sixth largest cause of disability worldwide in people aged 15-44 years[1] and is commonly mistaken for other diseases such as acute depression. Consequently, people may suffer with symptoms for years before receiving appropriate treatment and up to half of all ...
Copenhagen, Denmark (ots/PRNewswire) - - Patients Taking Exenatide Lost Weight While Patients Taking Insulin Glargine Gained Weight Eli Lilly and Company (NYSE: LLY) and Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced results from a study indicating that exenatide improves blood sugar levels as effectively as insulin glargine (Lantus(R), Sanofi ...
Natick, Massachusetts (ots/PRNewswire) - Boston Scientific Corporation (NYSE: BSX) today welcomed the results of two studies and an editorial published in today's edition of The New England Journal of Medicine (NEJM), all of which reaffirmed the safety and efficacy of drug-eluting stents. Commenting on the ...
The Bill & Melinda Gates Foundation
Seattle (ots/PRNewswire) - - Four Grants Support Development of Vaccines and Better Drugs, and Launch of New Medical Journal The Bill & Melinda Gates Foundation today announced four grants totaling US$68.2 million to help accelerate research on neglected tropical diseases, including hookworm, leishmaniasis, and trypanosomiasis, which kill or disable ...
Copenhagen, Denmark (ots/PRNewswire) - - Patients on exenatide lost weight, while insulin aspart patients gained weight - Eli Lilly and Company (NYSE: LLY) and Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced results from a study indicating that exenatide improves blood sugar levels as effectively as biphasic insulin aspart 30/70 (NovoMix 30(R), ...
Copenhagen, Denmark (ots/PRNewswire) - Eli Lilly and Company (NYSE: LLY), Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), and Alkermes, Inc. (Nasdaq: ALKS) today announced detailed results from a safety and efficacy study of the long-acting release (LAR) formulation of exenatide. Data from the study demonstrated ...
Copenhagen, Denmark (ots/PRNewswire) - - Twice as Many People With Uncontrolled Type 2 Diabetes Would Accept Insulin if Offered Exubera, Even in Countries Where Pens are Commonly Used, Additional Study Shows - Patients With Diabetes Gained Less Weight With Exubera Than With Injectable ...
Shire Pharmaceuticals Group Plc
Basingstoke, England (ots/PRNewswire) - - Not for Distribution in the United States The first anti-anaemia treatment produced in a human cell line, DYNEPO(R) (epoetin delta), can effectively control anaemia in patients with chronic kidney disease (CKD[x]) according to two Phase III studies presented for the first time today.(1),(2) Patients with kidney ...
New York (ots/PRNewswire) - - WSJ/Professor Pedro Nueno: "The drug could encourage diabetes sufferers to get treatment earlier and more often. This has such a tremendous advantage for a huge number of people worldwide. It is a real breakthrough." - PharmaBarometer: "Despite only being launched into the German market in May 2006, it has been immediately ...
Gateshead, England (ots/PRNewswire) - Medify Solutions Limited (Pink Sheets - MFYS), today received partner approval to release the current forward order book. These figures include all current and forward sales for both the UK and European operations. Medify Solutions Limited is contracted to deliver the MedifyRemote application to the UK and the Italian ...
Newcastle, England (ots/PRNewswire) - The Procter & Gamble Company (P&G) has been selected as the "Personal & Household Goods" Super Sector Industry Leader in the global Dow Jones Sustainability Index (DJSI) listings for the seventh year in a row. The Dow Jones Sustainability Indexes (DJSI), launched in 1999, are the first global indexes tracking the ...
Toronto, Canada (ots/PRNewswire) - Medify Solutions Limited (Pink Sheets - MFYS) today issued the latest investors update. The update is available to view on the company's website, www.medifysolutions.com under the latest news section. Company website : www.medifysolutions.com This news release contains forward-looking statements that are subject to certain risks and uncertainties that may cause actual results ...
Macclesfield, England (ots/PRNewswire) - - www.novelneuroprotection.com Aims to Increase Understanding of Acute Ischemic Stroke and the Potential Role of Neuroprotection - For Medical Media Only A new resource for the international medical community was launched in September 2006 by AstraZeneca, www.novelneuroprotection.com. This educational site aims to help healthcare professionals understand more about ...
Paris (ots/PRNewswire) - The New England Journal of Medicine publishes the international STEEPLE trial (Safety and Efficacy of Enoxaparin in Percutaneous Coronary Intervention (PCI): An International Randomized Evaluation), which showed that a single intravenous bolus of enoxaparin of 0.5 mg/kg is associated ...
Toronto, Canada (ots/PRNewswire) - - Mobile Access to Clinical Data now Available on BlackBerry Devices Medify Solutions Limited (Pink Sheets - MFYS) today announced that its product portfolio will be available on BlackBerry(R) handsets. The MedifyRemote application allows mobile access to patient notes and clinical systems in real time, helping doctors and nurses to provide better, more efficient and more ...